Jonathan Bullman

959 total citations
22 papers, 640 citations indexed

About

Jonathan Bullman is a scholar working on Physiology, Molecular Biology and Psychiatry and Mental health. According to data from OpenAlex, Jonathan Bullman has authored 22 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Physiology, 5 papers in Molecular Biology and 5 papers in Psychiatry and Mental health. Recurrent topics in Jonathan Bullman's work include Pain Mechanisms and Treatments (3 papers), Bipolar Disorder and Treatment (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Jonathan Bullman is often cited by papers focused on Pain Mechanisms and Treatments (3 papers), Bipolar Disorder and Treatment (3 papers) and Pharmacological Effects and Toxicity Studies (3 papers). Jonathan Bullman collaborates with scholars based in United Kingdom, United States and Germany. Jonathan Bullman's co-authors include Robert Lai, Jonathan Appleby, Thor Ostenfeld, Antonella Napolitano, Pauline Williams, Mike Aylott, Boris A. Chizh, Jie Wang, Jeffrey Price and Praveen Anand and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Pain.

In The Last Decade

Jonathan Bullman

22 papers receiving 614 citations

Peers

Countries citing papers authored by Jonathan Bullman

Since Specialization

Citations

This map shows the geographic impact of Jonathan Bullman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan Bullman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan Bullman more than expected).

Fields of papers citing papers by Jonathan Bullman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan Bullman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan Bullman. The network helps show where Jonathan Bullman may publish in the future.

Co-authorship network of co-authors of Jonathan Bullman

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan Bullman. A scholar is included among the top collaborators of Jonathan Bullman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan Bullman. Jonathan Bullman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Systemic Pharmacokinetics, Safety, and Preliminary Efficacy of Topical AhR Agonist Tapinarof: Results of a Phase 1 Study 2018 ·Clinical Pharmacology in Drug Development ·Robert Bissonnette, Lakshmi Vasist, Jonathan Bullman, (unknown), Geng Chen, Tomoko Maeda‐Chubachi	30
2	Adjustment of the area under the concentration curve by terminal rate constant for bioequivalence assessment in a parallel‐group study of lamotrigine 2018 ·British Journal of Clinical Pharmacology ·Jiansong Yang, Peiming Ma, Jonathan Bullman, Andrew Nicholls, Chao Chen	6
3	Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti‐CD3ε mAb in new‐onset type 1 diabetes mellitus patients 2018 ·British Journal of Clinical Pharmacology ·(unknown), Antonella Napolitano, (unknown), Kim Brown, Jonathan Bullman, David R. Inman, Bart Keymeulen, (unknown), (unknown), Alexander MacDonald, (unknown), Kevin Page, (unknown), Caroline O.S. Savage, Stefano Zamuner, André van Maurik	10
4	Ozanezumab Dose Selection for Amyotrophic Lateral Sclerosis by Pharmacokinetic-Pharmacodynamic Modelling of Immunohistochemistry Data from Patient Muscle Biopsies 2015 ·PLoS ONE ·Aliénor Berges, Jonathan Bullman, Stewart Bates, David Krull, Nicola Williams, Chao Chen	6
5	The relative bioavailability of 2 prototype fixed‐dose combination formulations for amlodipine and rosuvastatin in healthy white and Chinese subjects 2015 ·Clinical Pharmacology in Drug Development ·(unknown), Jonathan Bullman, (unknown), Annie Stylianou, (unknown)	3
6	A Randomized, Placebo-controlled Trial of the Analgesic Efficacy and Safety of the p38 MAP Kinase Inhibitor, Losmapimod, in Patients With Neuropathic Pain From Lumbosacral Radiculopathy 2014 ·Clinical Journal of Pain ·Thor Ostenfeld, Alok Krishen, Robert Lai, Jonathan Bullman, Jonathan Green, Praveen Anand, Joachim Scholz, (unknown)	34
7	Effect of Hemodialysis on Pharmacokinetics of Ezogabine/Retigabine and its N-Acetyl Metabolite in Patients with End Stage Renal Disease 2014 ·Current Clinical Pharmacology ·Debra Tompson, (unknown), Jonathan Bullman, Christopher Crean, (unknown)	3
8	Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET 2014 ·Journal of Psychopharmacology ·Khanum Ridler, Roger N. Gunn, Graham E. Searle, Julien Barletta, Jan Passchier, (unknown), William Hallett, Sharon Ashworth, (unknown), (unknown), Italo Poggesi, Jonathan Bullman, Emiliangelo Ratti, Marc Laruelle, Eugenii A. Rabiner	20
9	Human microdose evaluation of the novel EP1 receptor antagonist GSK269984A 2012 ·British Journal of Clinical Pharmacology ·Thor Ostenfeld, Claire Beaumont, Jonathan Bullman, (unknown), Philip D. Jeffrey	13
10	Pharmacokinetics and central nervous system effects of the novel dual NK₁/NK₃ receptor antagonist GSK1144814 in alcohol‐intoxicated volunteers 2012 ·British Journal of Clinical Pharmacology ·(unknown), Justin L. Hay, Jonathan Bullman, (unknown), Kimberly J. Nahon, Erica S. Klaassen, (unknown), Joop van Gerven	10
11	Analgesic efficacy and safety of the novel p38 MAP kinase inhibitor, losmapimod, in patients with neuropathic pain following peripheral nerve injury: a double‐blind, placebo‐controlled study 2012 ·European Journal of Pain ·Thor Ostenfeld, Alok Krishen, (unknown), Jonathan Bullman, Amanda Baines, (unknown), Praveen Anand, (unknown)	44
12	A Randomized, Controlled Study to Investigate the Analgesic Efficacy of Single Doses of the Cannabinoid Receptor-2 Agonist GW842166, Ibuprofen or Placebo in Patients With Acute Pain Following Third Molar Tooth Extraction 2011 ·Clinical Journal of Pain ·Thor Ostenfeld, Jeffrey Price, Massimo Albanese, Jonathan Bullman, (unknown), Ingo Meyer, Rachel Leeson, (unknown), Luigi Ziviani, Pier Francesco Nocini, Stefano Milleri	100
13	Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers 2011 ·Epilepsia ·Jonathan Bullman, Andrew Nicholls, (unknown), (unknown), Alain Vuong, James D. Miller, (unknown), John A. Messenheimer	29
14	701 RANDOMISED, PLACEBO‐CONTROLLED, PARALLEL‐GROUP STUDY OF THE EFFECT OF SB‐705498, A TRPV1 RECEPTOR ANTAGONIST, ON PAIN FOLLOWING THIRD MOLAR TOOTH EXTRACTION 2009 ·European Journal of Pain ·James A. Palmer, Robert Lai, Nicola Thomas, Jonathan Bullman, Zeeshan Ali, Amanda Baines, Jonathan Appleby	1
15	702 A RANDOMISED, TWO‐PERIOD CROSS‐OVER STUDY TO INVESTIGATE THE EFFICACY OF THE TRPV1 ANTAGONIST SB‐705498 IN ACUTE MIGRAINE 2009 ·European Journal of Pain ·B.A. Chizh, James A. Palmer, Robert Lai, (unknown), Jonathan Bullman, Amanda Baines, Antonio Napolitano, Jonathan Appleby	20
16	The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans 2007 ·Pain ·Boris A. Chizh, (unknown), Antonella Napolitano, Jie Wang, (unknown), Mike Aylott, Jonathan Bullman, (unknown), Robert Lai, Pauline Williams, Jonathan Appleby	199
17	Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects 2006 ·British Journal of Clinical Pharmacology ·Jagdev Sidhu, Sarah A. Job, Jonathan Bullman, Emma Francis, Richard Abbott, John A. Ascher, Jochen G.W. Theis	24
18	(765) 2006 ·Journal of Pain ·B.A. Chizh, Antonio Napolitano, Mike O’Donnell, (unknown), (unknown), Robert Lai, Mike Aylott, Jonathan Bullman, Earl L. Gray, Pauline Williams, Jonathan Appleby	10
19	Lack of Pharmacokinetic Interaction between Oxcarbazepine and Lamotrigine 2005 ·Neuropsychopharmacology ·Jochen G.W. Theis, Jagdev Sidhu, Joanne Palmer, Sarah A. Job, Jonathan Bullman, John A. Ascher	19
20	Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers 2004 ·Current Medical Research and Opinion ·(unknown), (unknown), Jonathan Bullman, (unknown), Simon J. Summers, (unknown), Jagdev Sidhu	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact